Compounds for the treatment of neurodegenerative disorders
AssigneeFisons Limited
InventorsRonald C. Griffith, Robert J. Murray, Michael Balestra, Donald Mathisen
Life of this patent
Estimating the term…
Abstract
(S)-.alpha.-phenyl-2-pyridineethanamine, and its pharmaceutically acceptable derivatives, are useful in the treatment of neurodegenerative disorders, and exhibit linear pharmacokinetics.
Claims18
(S)-.alpha.-phenyl-2-pyridineethanamine, which is greater than 90% enantiopure, and pharmaceutically acceptable derivatives thereof.
(S)-.alpha.-phenyl-2-pyridineethanamine, which is greater than 99% enantiopure, and pharmaceutically acceptable derivatives thereof.
(S)-.alpha.-phenyl-2-pyridineethanamine, and pharmaceutically acceptable derivatives thereof.
(S)-.alpha.-phenyl-2-pyridineethanamine (S)-malate which is greater than 90% enantiopure.
(S)-.alpha.-phenyl-2-pyridineethanamine (S)-malate which is greater than 99% enantiopure.
(S)-.alpha.-phenyl-2-pyridineethanamine (S)-malate.
(S)-.alpha.-phenyl-2-pyridineethanamine benzoate which is greater than 90% enantiopure.
(S)-.alpha.-phenyl-2-pyridineethanamine benzoate which is greater than 99% enantiopure.
(S)-.alpha.-phenyl-2-pyridineethanamine benzoate.
Dependencies are inferred from the claim text.